Drug Trial Radar · NCT05513950
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jan 25, 2023
Primary completion
Jun 17, 2024
Study completion Jun 17, 2024
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it. The body's immune response to the study drug was evaluated. Chiesi conducted this study in patients affected by idiopathic pulmonary fibrosis (IPF, a progressive and chronic lung disease). Chiesi performed this study to establish the drug doses that would be suitable for future studies (a dose finding study).
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
CHF10067 starting dose -- 1000mg (Cohort A)Biological
Intravenous administration of a starting dose of the monoclonal antibody
CHF10067 intermediate dose -- 2000mg (Cohort B)Biological
Intravenous administration of an intermediate dose of the monoclonal antibody
CHF10067 high dose -- 3000mg (Cohort C)Biological
Intravenous administration of a high dose of the monoclonal antibody
PlaceboDrug
Intravenous administration of a physiological solution as placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1_Subjects With Adverse Event (AE); Non-Serious AEs and Serious AEsTime frame: From pre-dose (baseline) up to day 84.
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
PHI University Clinic of Pulmonology and Allergology
Skopje, North Macedonia
Medical Center of Limited Liability Company "Arensia Exploratory Medicine", department of Clinical Trials
Kyiv, Ukraine
Queen Elizabeth Hospital - NIHR Birmingham Clinical Research Facility - University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Royal Papworth Hospital NHSFT - Cambridge Biomedical Campus
Cambridge, United Kingdom
University of Dundee, NHS Tayside - Ninewells Hospital & Medical School
Dundee, United Kingdom
Interstitial Lung Disease Research - NHS Lothian - Royal Infirmary of Edinburgh,
Edinburgh, United Kingdom
Liverpool Clinical Research Facility - Liverpool University Hospital Foundation Trust
Liverpool, United Kingdom
Medicines Evaluation Unit - The Langley Building
Manchester, United Kingdom
University Hospital Southampton - Department of Respiratory Medicine
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.